Therefore, high c-Myb expression is beneficial in luminal breast cancer and reducing c-Myb protein levels via antisense therapy could be detrimental; as shown above, in vitro reduction of c-Myb via RNAi increased tumorigenesis. Here, MYB is linked to breast cancer.